Business Wire

VIKING-MALT

1.2.2024 09:01:30 CET | Business Wire | Press release

Share
Viking Malt partners up with Improvin’ to reduce supply chain emissions in barley

Viking Malt has set Science Based Targets, committing to a 42% reduction in greenhouse gas emissions from its own activities (Scope 1 & 2) by 2030. However, the majority of Viking Malt’s total emissions, 87%, are Scope 3 emissions from their suppliers, mainly occurring on-farm.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201888552/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Viking Malt, a globally acknowledged producer of malt, is introducing a new sustainability performance platform, developed by the Swedish technology company Improvin’. Photo: Viking Malt.

Many of Viking Malt’s customers are large enough to have reduction targets covering even their Scope 3 emissions. To support their clients in achieving this goal, Viking Malt is committed to working with its stakeholders across the supply chain, identifying areas for emissions reductions and adjusting processes and practices.

With barley sourced from farmers across Finland, Sweden, Denmark, Poland and Lithuania, Viking Malt has been seeking ways to effectively measure and reduce these emissions.

Annika Wilhelmson, VP of Sustainability, Innovation & Marketing at Viking Malt Group: “Our farmers are central to our sustainability journey. With this new platform, we're empowering over 1200 farmers across Europe to actively engage in climate-smart and sustainable farming. This enables us to track and validate the impact of their sustainable practices effectively and fosters a collaborative approach to reducing emissions.”

The new platform provides Viking Malt with a detailed overview of the farms’ sustainability performance, setting a foundation for sustainable farming initiatives in which growers can adjust their practices based on feedback that builds on real-time data.

With the platform’s scalable data collection, farmer reporting becomes easy. “We want our farmers to be able to focus on sustainable and profitable agriculture, not extensive reporting,” Annika emphasizes.

The new platform equips Viking Malt with a verified ingredient footprint, biodiversity data and supply chain insights that they can share with their network of breweries, distilleries and food manufacturers. Viking Malt expects this transparency to drive positive change across the industry.

Annika concludes: “Our commitment to sustainable food and beverage production is shared by the industry. Success requires a collaborative approach throughout, and even beyond, our own value chain. We're excited to lead and inspire our partners and customers on this journey.”

Niklas Wallsargård, CEO of Improvin’ adds: “We're both proud and excited to work with Viking Malt, a family company showing deep commitment to drive sustainable impact through their products. Together, we can drive a meaningful change in this industry.”

About Viking Malt

Viking Malt is a globally acknowledged producer of malt for breweries, distilleries, and food manufacturers. With six malt houses in Sweden, Denmark, Finland, Lithuania, and Poland, Viking Malt offers a diverse range of malt varieties, catering to the unique needs of their customers. The company advocates for increased sustainability through malt by promoting regenerative farming practices, continuously improving energy and water efficiency in the malting process, reducing emissions, and leading innovation in new types of malts.

About Improvin’

Improvin’ is a Swedish technology company providing a sustainability performance platform for the agri-food industry. Food brands, processors and mills use the platform to quantify, verify and report emissions from their primary production and collaborate with their suppliers to reduce emissions and enhance biodiversity. Improvin's digital infrastructure enables agri-food businesses to incorporate sustainability into their existing sourcing processes while meeting regulatory standards for reporting with primary data.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240201888552/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye